MedTrace Logo

Dexmedetomidine Wound Infiltration in Cesarean Section

NCT03382938 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-03-19

No results posted yet for this study

Summary

The effects of four different wound infiltration protocols in cesarean section will be investigated on parturient' pain intensity, PCA morphine consumption given, side effects and parturient' overall satisfaction.

One group will receive for wound infiltration dexmedetomidine, the second ropivacaine, the third dexmedetomidine combined with ropivacaine, while the last one will receive normal saline (placebo group).

Conditions

  • Postoperative Pain

Interventions

DRUG

Dexmedetomidine

WOUND INFILTRATION IN CESAREAN SECTION

DRUG

Ropivacaine

WOUND INFILTRATION IN CESAREAN SECTION

DRUG

Dexmedetomidine - Ropivacaine

WOUND INFILTRATION IN CESAREAN SECTION

OTHER

0,9% saline

placebo WOUND INFILTRATION IN CESAREAN SECTION

Sponsors & Collaborators

  • Attikon Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-23
Primary Completion
2025-12-20
Completion
2026-11-20

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03382938 on ClinicalTrials.gov